Citations

Clear

572 citation(s) found for "Silva, P".

Detergent‐Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans
Wright, Benjamin L., Crowell, Michael D., Luo, Huijun , Masuda, Mia Y., Itoh, Naohiro , Folmes, Karalyn, Stoa, Jean M., Buras, Matthew R., Sherman, Will, Baheti, Saurabh , Bowman, Dean, Hill, Lindsey C., Vela, Marcelo F. , Kita, Hirohito, Rank, Matthew A. , Horsley‐Silva, Jennifer L., Doyle, Alfred D. , Horsley-Silva, Jennifer L, Kita, H , Wright, Benjamin L. , Crowell, Michael D. , Masuda, Mia Y. , Stoa, Jeannie, Buras, Matthew, Kita, Hirohito , Hill, David B. , Horsley‐Silva, Jennifer L.

Mayo Clinic

Allergy | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/all.70437 | PMID 42397127 Get It

ABSTRACT Background Eosinophilic esophagitis is associated with epithelial barrier dysfunction. Epidemiologic studies suggest environmental factors promote disease pathogenesis. The common household detergent sodium dodecyl sulfate (SDS) induces epithelial barrier dysfunction and eosinophilic inflammation in mice. We hypothesized that acute SDS exposure would compromise the esophageal mucosal barrier in humans. Methods Healthy adults brushed with 2 g of an SDS‐containing toothpaste. Esophageal impedance was measured continuously pre‐/post‐toothbrushing to assess the effect of toothpaste on epithelial barrier function. SDS was measured in saliva using a methylene blue anionic substances assay. Participants completed 1‐h esophageal string tests (ESTs) pre‐/post‐toothbrushing and protein isolates from EST eluates from the proximal and distal esophagus were analyzed by tandem mass tag mass spectrometry. Results Ten of twelve subjects completed the clinical study. SDS in the initial expectorate measured immediately after toothbrushing varied markedly (median: 321.40 μg/mL; range: 169.90–1243.00 μg/mL) and was detectable in saliva in 80% of subjects (median: 9.55 μg/mL; range: 0–123.40 μg/mL) at 60 min post toothbrushing. Esophageal mucosal impedance decreased within 30 min of toothbrushing ( p < 0.01). Toothbrushing increased salivary viscosity and proteins associated with mucosal defense in EST eluates. The tight junction pathway was downregulated while the salivary secretion and complement and coagulation cascades pathways were upregulated in the proximal esophagus. Conclusion In healthy individuals, SDS remained detectable in saliva for a prolonged period after toothbrushing at concentrations previously shown to disrupt esophageal epithelial barrier function in vitro. Toothbrushing with an SDS‐containing toothpaste was associated with reduced esophageal mucosal impedance, altered salivary properties, and activated mucosal immune responses.
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia
Gaballa, Mahmoud R. , Julian, Kelley , Afrough, Aimaz , Hansen, Doris K. , Goel, Utkarsh , Corraes, Andre De Menezes Silva, Dima, Danai , Rana, Masooma , Hosoya, Hitomi , Mikkilineni, Lekha , Fogel, Lindsay , Raza, Shahzad, Zanwar, Saurabh , Sannareddy, Aishwarya, Borogovac, Azra , Green, Kimberly M , Biran, Noa, Shune, Leyla, Ouchveridze, Evguenia, DeJarnette, Shaun, Ferreri, Christopher J, Richards, Tiffany, Bal, Susan , Ye, Jing Christine, Shain, Kenneth H. , Harada, Ken , Avila, Gabriel De, Voorhees, Peter, Khouri, Jack , Sidana, Surbhi , Lin, Yi, Patel, Krina K. , Sborov, Douglas W. , Gaballa, Mahmoud , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Zanwar, Saurabh S , Borogovac, Azra , Davis, James A , Green, Kimberly , Zolotov, Eli , Herr, Megan M. , Abid, Muhammad Bilal , Bal, Susan , Ali, Hossam M , Kaur, Gurbakhash , Shain, Kenneth H , Castaneda Puglianini, Omar , Hassan, Hamza , Anderson, Larry D , Khouri, Jack , Sidana, Surbhi , Portuguese, Andrew J , Janakiram, Murali , Lee, Hans C , Patel, Krina , Sborov, Douglas W , Dima, Danai , Hosoya, Hitomi , Rana, Masooma S , Julian, Kelley L , Hansen, Doris K , Corraes, Andre De Menezes Silva , Raza, Shahzad , Banerjee, Rahul , Pasvolsky, Oren , Sannareddy, Aishwarya , Davis, James A. , Biran, Noa , Zolotov, Eli , Shune, Leyla , Atrash, Shebli , Ferreri, Christopher J. , Richards, Tiffany, Abid, Muhammad Bilal , Ali, Hossam M. , Ye, Jing Christine, Richard, Shambavi , Kaur, Gurbakhash , Puglianini, Omar Castañeda , Rossi, Adriana , Hassan, Hamza , Anderson, Larry D. , Voorhees, Peter M. , Portuguese, Andrew J. , Janakiram, Murali , Lee, Hans C. , Grajales‐Cruz, Ariel

Mayo Clinic

Blood Advances | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020826 | PMID 42392158 Get It

Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as 'active' (≥5% circulating plasma cells within 30 days of BsAb initiation) or 'historical'. In a heavily pretreated population, patients received teclistamab (37%), elranatamab (11%), talquetamab as a line of therapy (Tal LOT, 42%), or talquetamab as bridging therapy to CAR-T (Tal Bridge, 11%). Cytokine release syndrome (CRS) was grade 1-2 in 56% and grade 3-4 in 4%, whereas neurotoxicity was grade 1-2 in 16% and grade 3-4 in 5%. Among 110 evaluable patients, the overall response rate (ORR) was 55%, including 61% with Tal LOT, 58% with Tal Bridge, 46% with elranatamab, and 33% with teclistamab. With a median follow-up of 8.3 months, talquetamab demonstrated superior survival. Tal LOT showed a median progression-free survival (mPFS) of 5.5 months and a median overall survival (mOS) of 11.5 months, and both were unreached in the Tal Bridge cohort. In contrast, teclistamab and elranatamab showed a mPFS of 1.2 and 1.6 months and mOS of 8.1 and 3.6 months, respectively (P=0.007, P=0.023). In active PCL, Tal LOT achieved mPFS/mOS of 6.9/12.2 months versus 0.7/1.4 months with teclistamab and 1.0/3.1 months with elranatamab, respectively (P&lt;0.001, P=0.002). Multivariable analysis associated active PCL with worse survival and Tal LOT with improved outcomes. BsAbs were safe in PCL, with talquetamab showing superior outcomes compared with BCMA-directed BsAbs.
Surgical Management of Non‐Allergic Rhinitis—An EAACI Task Force Position Paper
Lundberg, Marie , Waterschoot, Julie van , Moyaert, Mathilde, Chaker, Adam, Gevaert, Philippe , Hagemann, Jan , Hox, Valérie, Kleijwegt, Maarten, Klimek, Ludger , Lal, Devyani, Maza‐Solano, J. , Pfaar, Oliver, Ryser, Fabio S. , Silva, Diana, Toppila‐Salmi, Sanna , Wikstén, Johanna , Reitsma, Sietze, Gerven, Laura Van , van Waterschoot, Julie , Ryser, Fabio Simon , Shiappoli, Michele , Toppila-Salmi, Sanna , Wikstén, Johanna , Van Gerven, Laura , Hox, Valérie , Kleijwegt, Maarten C. , Lal, Devyani , Pfaar, Oliver , Reitsma, Sietze

Mayo Clinic

Allergy | July 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/all.70424 | PMID 42385211 Get It

ABSTRACT Non‐allergic rhinitis is a frequent yet underdiagnosed cause of chronic nasal symptoms, including nasal congestion, rhinorrhoea, and upper airway hyperreactivity. Its pathophysiology involves neurogenic dysregulation, leading to excessive mucus production and vasodilation. While medical therapy remains first‐line, some patients experience persistent symptoms requiring surgical intervention. This review outlines key surgical options for refractory non‐allergic rhinitis: inferior turbinate (IT) reduction, vidian neurectomy, and posterior nasal nerve (PNN) ablation. IT reduction—performed using cold instruments, radiofrequency, laser, coblation, or microdebrider—remains the cornerstone treatment for nasal obstruction, offering durable symptom relief with low complication rates. Vidian neurectomy effectively reduces rhinorrhoea but carries risks of ocular dryness and transient facial numbness, limiting its indication to severe, refractory cases. PNN interventions, including cryotherapy, cold‐instrument techniques, and radiofrequency, provide a minimally invasive, outpatient alternative that selectively targets nasal parasympathetic and sensory fibers while sparing lacrimal innervation, yielding significant and lasting symptom improvement. Surgical management of non‐allergic rhinitis is effective and safe when tailored to symptom profile, anatomy, and prior medical treatment response. Advances in endoscopic and minimally invasive approaches have reduced complications, establishing these procedures as integral options in comprehensive non‐allergic rhinitis care.
Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
Lim, Kenneth J C , Kumar, Shaji, Chhabra, Saurabh , Tan, Melinda Si Yun , Dooley, Katharine, Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Kourelis, Taxiarchis, Warsame, Rahma, Abdallah, Nadine , Bergsagel, P. Leif, Yadav, Udit, Geyer, Susan M. , Ailawadhi, Sikander, Lin, Yi, Zanwar, Saurabh , Chhabra, Saurabh , Tan, Melinda , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Wiedmeier-Nutor, Julia E , Geyer, Susan , Rajkumar, S Vincent , Fonseca, Rafael , Zanwar, Saurabh S , Lim, Kenneth J C , Kumar, Shaji , Parrondo, Ricardo D , Dooley, Katharine , Stephens, H. J. B., Kourelis, Taxiarchis , Warsame, Rahma , Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Rajkumar, S. Vincent , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | June 26, 2026 | Volume: 101 | Issue: 9 | Pages: 2269-2279

10.1002/ajh.70425 | PMID 42351384 Get It

ABSTRACT Ciltacabtagene autoleucel (cilta‐cel) has demonstrated excellent efficacy and long‐term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard‐of‐care cilta‐cel across the three Mayo clinic centers. Patients with a follow‐up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure ( n = 52), 69% had progressive disease and 31% had a non‐relapse mortality (NRM) event. In patients without early treatment failure ( n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA‐directed therapy, presence of extramedullary disease and a CAR‐HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta‐cel in earlier lines of treatment (1–3 vs. 4 or more) demonstrated comparable PFS (12‐month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high‐risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high‐risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.
Emerging directions in tauopathy research
Wildsmith, Kristin R., Alladi, Suvarna, Bertucci, Taylor, Bowles, Kathryn R. , Boxer, Adam, Brummet, Jennifer, DeVos, Sarah L., Diaz, Kristophe , Duff, Karen, Duran‐Aniotz, Claudia, Farrell, Kurt, Fontana, Igor C., Franzmeier, Nicolai, Frost, Bess, Petrucelli, Leonard, Rexach, Jessica, Reyderman, Larisa, Rommel, Amy, Bohórquez, Sandra M. Sanabria, Schöll, Michael, Schneider, Anja, Silva, Rohan de , Snyder, Heather M. , VandeVrede, Lawren, Varga, Andrew W, Vogel, Jacob W., Yeh, Felix L. , Yoo, Andrew S., Carrillo, Maria C., Duff, Karen , Bertucci, Taylor , Mahinrad, Simin , Buée, Luc , Alladi, Suvarna , Boche, Delphine , DeVos, Sarah L. , Dreyer, Anna J. , Duran‐Aniotz, Claudia , Durrant, Claire S. , Farrell, Kurt , Fontana, Igor C. , Franzmeier, Nicolai , Frost, Bess , Horie, Kanta , Kaňovský, Petr , Kao, Aimee W. , Mahinrad, Simin , Malpetti, Maura , Morris, Huw R. , Palleis, Carla , Petrucelli, Leonard , Rexach, Jessica E. , Reyderman, Larisa, Rowe, James B. , Bohórquez, Sandra Sanabria , Sato, Chihiro , Schneider, Anja , VandeVrede, Lawren , Varga, Andrew W. , Vogel, Jacob W. , Yoo, Andrew S.J. , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | June 22, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71431 | PMID 42324487 Get It

Abstract The Tau Global Conference 2025, hosted by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation, convened international experts from academia, industry, government, and philanthropy to explore advances and challenges in tauopathy research. The meeting highlighted progress across tau biology, including emerging models of tau regulation, degradation, and propagation; advances in biomarker development for the diagnosis and staging of tauopathies; and evolving therapeutic strategies targeting diverse aspects of tau pathophysiology. Discussions also emphasized the importance of cross‐sector collaboration, and global initiatives to address disparities in tau research. This report synthesizes key insights from the conference and underscores the critical role of interdisciplinary, biomarker‐driven, and globally inclusive approaches in accelerating the translation of tau research into effective clinical applications.
Anatomic Basis for Imaging Assessment of the Postsurgical Anterolateral Abdominal Wall
Montel, Daniel B. , Oliveira, I. , Salazar, Max Orsi , FIOROT, VINICIUS CASTRO DE REZENDE , Gontijo, Cássio Eduardo da Silva , Horvat, Natally , Venâncio, Priscilla Cláudia Raddo , Barbosa, Manoel Henrique Fonseca , Chaves, Filipe Tomishige , Pozzer, Gabriel Guilherme Nunes , Lewin, Fábio , Montel, Daniel Borges , de Oliveira, Igor Rother César , Orsi Salazar, Max , Horvat, Natally

Mayo Clinic

RadioGraphics | June 11, 2026 | Volume: 46 | Issue: 7 | Pages: No page available

10.1148/rg.250061 | PMID 42275240 Get It

A structured approach for interpreting postoperative imaging of the anterolateral abdominal wall integrates anatomic knowledge with surgical techniques and their associated complication patterns.
Correction: Plasma Aβ42/p-Tau217 ratio and p-Tau217 independently predict CSF-defined Alzheimer's disease pathology in a Brazilian admixed cohort
Silva, Marjorie Cristina da Rocha, Aventurato, Ítalo Karmann , Santos, Luis Eduardo, Silva, Ananssa Maíra dos Santos, Pinheiro, Thaís Lopes, Fernandes, Gustavo Bruniera Peres , Felice, Fernanda Guarino De, Balthazar, Marcio L. F., Rizzi, Liara , Ribeiro, Isadora Cristina , Pinheiro, TC , Balthazar, Marcio Luiz Figueredo

Mayo Clinic

Frontiers in Aging Neuroscience | June 9, 2026 | Volume: 18 | Issue: No issue available | Pages: No page available

10.3389/fnagi.2026.1875333 | PMID 42343890 Get It

A constraint‐normalized robustness index for HDR brachytherapy
Portocarrero‐Bonifaz, Andres, Viviers, Emma, McLemore, L., Sowards, Keith , Silva, Scott R. , Nieto, Karina , Mclemore, Luke, Bonifaz, Andrés Portocarrero

Mayo Clinic

Medical Physics | June 8, 2026 | Volume: 53 | Issue: 6 | Pages: No page available

10.1002/mp.70506 | PMID 42253208 Get It

Abstract Background Geometric uncertainties in high‐dose‐rate brachytherapy, including applicator displacement, catheter deflection, and interstitial needle spread, produce dose deviations that are patient and plan specific. Unlike external beam radiotherapy, where robustness evaluation frameworks are increasingly standardized, high dose rate brachytherapy lacks a normalized aggregate metric for quantifying plan sensitivity to geometric perturbations. Purpose To define a bounded, dimensionless robustness index for per‐fraction evaluation of high dose rate brachytherapy plans that is normalized to clinically meaningful dose‐limit constraints, incorporates dose‐dependent penalty sensitivity, and provides both a full‐scenario severity measure and a dose‐threshold‐filtered variant. Methods Geometric perturbation scenarios (translations, rotations, radial expansion/contraction, catheter deflection, and combined modes) are applied to source dwell positions. For each organ at risk, a convex‐transformed, constraint‐normalized penalty quantifies the fraction of the remaining margin to the dose‐limit constraint consumed per scenario. For target volumes, a prescription‐normalized piecewise penalty captures under‐coverage and excessive dose escalation. The Robustness Index is defined as one minus the mean scenario penalty, yielding a value in [0,1]. Results The framework produces structure‐independent, interpretable indices where a Robustness Index indicates that scenarios consume on average only 10% of the normalized remaining margin to the dose‐limit constraint. A threshold‐filtered variant evaluates robustness among only those scenarios that exceed a clinically specified dose level. Conclusions The proposed robustness index provides a standardized, clinically anchored metric for high dose rate brachytherapy plan evaluation under geometric uncertainty, complementing existing dose volume histogram based reporting with a single interpretable number per structure.